Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GRANT: GLARGEN vs NPH Insulin in Type 2 Diabetes
NCT06999551Phase 4Not yet recruiting
- Sponsor
- Les Laboratoires des Médicaments Stériles
- Start
- Jul 2025
- Primary completion
- Dec 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Glargen in type 2 diabetes mellitus (T2DM), sponsored by Les Laboratoires des Médicaments Stériles. Primary endpoint: glycaemic variability on insulin glargine versus NPH insulin at 12 weeks. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
Glargen
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06999551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06999551.